Expert Interview
A Second Look: Discussing the potential of remyelination and neuronal repair in multiple sclerosis patients following treatment with CNM-Au8® 30 mg and the results from the VISIONARY-MS Trial
Ticker(s): CLNNInstitution: University of South Alabama Health
- Director of the Neuroimmunology and MS Clinic, Director of the Neurology Residency Program; Assistant Professor of Neurology at University of South Alabama.
- Treats approximately 750 patients with Multiple Sclerosis.
- Confirms an infusion center associated with practice; and has prescribed Ocrevus, Kesimpta and Briumvi.
- Clinical interests include Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder (NMOSD), Transverse myelitis, Optic neuritis.
- Serves as principal investigator on several clinical trials and has delivered abstract presentations at several national meetings.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
